exRNAdisease

General Information

Database ID:

exR0081463

RNA Name:

SLC25A3

RNA Type:

mRNA

Chromosome:

chr12

Starnd:

Coordinate:

Start Site(bp):

98593591

End Site(bp):

98606379

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABHD17A	chr19	1876810	1885547	-
ABT1	chr6	26596953	26600739	+
AC023055.1	chr12	55757275	55827546	-
AC091167.2	chr15	90249556	90272208	+
AC092835.1	chr2	95207535	95259774	+
AC093525.2	chr16	2496032	2520218	+
AC245033.1	chr15	82536788	82573194	-
ACTA1	chr1	229431245	229434098	-
ACTB	chr7	5527148	5563784	-
ACTG1	chr17	81509971	81523847	-
ACTG2	chr2	73892314	73919865	+
ACTR2	chr2	65227753	65271253	+
ACY1	chr3	51983340	51989197	+
ADIPOR1	chr1	202940826	202958572	-
AHCY	chr20	34280268	34311802	-
AICDA	chr12	8602170	8612867	-
AKAP12	chr6	151239967	151358559	+
AKIRIN1	chr1	38991276	39006059	+
AL117348.2	chr1	225886696	225924278	-
AL355315.1	chr10	97584374	97673910	+
AL355987.1	chr9	136738167	136748453	-
AL358113.1	chr9	69035747	69255187	+
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-205-5p	chr1	209432166	209432187	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC007406.5	chr12	273954	277123	-
AC087239.1	chr12	25385670	25386241	-
AC106886.2	chr16	30740667	30751381	+
AC245014.3	chr1	145281116	145281462	+
AC245033.4	chr15	82533175	82540008	-
AD000090.1	chr19	35557956	35581954	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference